Skip to main content

Search

Search people, articles, bills, and more

New Jersey Office of Attorney General logo

New Jersey Office of Attorney General

njoag.gov

GovernmentProvenance not yet reviewedOfficial source

1 story credited to New Jersey Office of Attorney General

Latest story Apr 16, 2026 · on ChamberLight since Apr 2026

A story can appear as several articles (copies of the same piece), so counts of stories and of articles differ.

Compare with another source

Scores for New Jersey Office of Attorney General

Credibility

Not enough stories yet: 1 of 10.

How this is measured

Political lean

Not enough stories yet: 1 of 10.

How this is measured

Originality

Not enough stories yet: 1 of 10.

How this is measured

Writing quality not enough rated stories yet: 1 of 10. How it is measured

Scores last checked Sep 25, 2026.

Stories ChamberLight collected, by month

Stories credited to New Jersey Office of Attorney General, by publication date. ChamberLight collects articles that mention the officials it tracks, so this shows its own coverage of this source, not how much the source publishes.

  • Stories from New Jersey Office of Attorney General
  • Shaded: ChamberLight collected no stories, or almost none, from any outlet (a gap in its collection, not in the outlet’s publishing)
Show as a table
MonthStoriesAll outlets
April 202611,805
May 20260none collected
June 20260none collected
July 20260none collected
August 202601 (collection gap)
September 20260598

Top topics

Share of this source’s stories tagged with each topic. A story can carry several topics, so the shares do not add up to 100%.

  • Economy1

    100% of 1 stories · 24% across all outlets

  • Ethics/Corruption1

    100% of 1 stories · 56% across all outlets

  • Healthcare1

    100% of 1 stories · 7% across all outlets

The thin mark on each bar is the topic’s share across all outlets.

Who they cover

Party of the officials these stories are mainly about, across all 2 officials named. A story counts once for each official it is mainly about, so the split is over 2 story–official pairs, from 1 story.

  • Democrat50% · 1 pair
  • Party not recorded50% · 1 pair

Most covered

Stories mainly about each official, and their share of the source’s 1 story.

  1. 1Keith Davenport–1 story · 100%
  2. 2Mikie SherrillD1 story · 100%

Article tone

ChamberLight’s article analysis assigns each story a tone toward the official it covers. It describes the coverage of that official, not New Jersey Office of Attorney General’s stance, and reader votes do not change it. 1 story.

Good Look
1 (100%)
Mixed
0 (0%)
Informational
0 (0%)
Bad Look
0 (0%)

Challenges to these scores

No one has challenged a score on this page yet. Anyone can; editors publish every outcome here.

Articles served from njoag.gov

2

AG Davenport, Bipartisan Coalition Support Federal Rule to Increase PBM Transparency in Drug Pricing

Pharmacy Benefit Managers Affect Affordability of Prescription Drugs, Hurting Patients and Taxpayers For Immediate Release: April 16, 2026 Office of the Attorney General – Jennifer Davenport, Attorney General For Further Information: Media Inquiries- Allison Inserro OAGpress@njoag.gov View Comment Letter TRENTON — Attorney General Jennifer Davenport and a bipartisan coalition of 44 other attorneys general filed a comment letter in support of a proposed U.S. Department of Labor rule that would require transparency from pharmacy benefit managers (PBMs) that service employer-funded health plans. PBMs are third-party administrators of prescription drug programs for health insurers and health plans. Governor Mikie Sherrill called for more oversight into these middlemen in her budget address in March, noting that New Jersey’s Medicaid program would save $20 million annually if PBMs were not allowed to inflate prices. “We all feel the financial pain of rising drug prices, but it doesn’t have to be this way,” said Attorney General Davenport. “We’re standing together with a bipartisan coalition of attorneys general in urging the federal government to increase oversight over PBMs. Our office is committed to ensuring that PBMs are following the law—and to hold them accountable when they don’t.” Created in the late 1960s to process prescription drug claims, PBMs now play a far broader and more powerful role in the health care system by managing prescription drug benefits for health insurers. This includes, among other things, negotiating rebates and reimbursements with drug manufacturers and determining which drugs are covered and at what cost. Approximately 136 million Americans receive health coverage through an employer—either their own job or a family member’s—and the proposed rule responds to concerns that employers often lack visibility into how PBMs are making money or why drug costs change. It would require PBMs to disclose twice a year how they generate revenue and would give employers the right to audit them. PBMs have also long sought to avoid state regulation by claiming federal preemption under ERISA. The attorneys general urge the Department of Labor to clarify that the proposed rule does not preempt state PBM transparency laws. PBMs have long sought to avoid state regulation by claiming federal preemption under the Employee Retirement Income Security Act of 1974 (ERISA). Further, in the comment letter, the attorneys general ask the Department of Labor to commit to collaborating with state regulators to achieve transparency. According to the coalition, the final rule should mention that nothing in the rule is intended to prevent the Department of Labor from referring matters to state attorneys general, requesting their investigative or enforcement assistance, or coordinating with them when the department discovers violations of state law. Today, the top three PBMs manage approximately 80% of prescription drug claims. Due to the power imbalance held by PBMs and the negative effects of such power on drug pricing, all fifty states, the District of Columbia, and Puerto Rico have enacted laws to rein them in. In recent years, New Jersey has enacted several laws that apply to PBMs, including one that requires PBMs to report pricing information to the Division of Consumer Affairs and provides for civil penalties if they fail to report. In submitting today’s comment letter, Attorney General Davenport joins the attorneys general of Alaska, American Samoa, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, the District of Columbia, Georgia, Hawaii, Idaho, Illinois, Indiana, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Vermont, Virginia, Washington, West Virginia, and Wyoming. ### The post AG Davenport, Bipartisan Coalition Support Federal Rule to Increase PBM Transparency in Drug Pricing appeared first on New Jersey Office of Attorney General.

Apr 16, 202610 votes

AG Davenport, Bipartisan Coalition Support Federal Rule to Increase PBM Transparency in Drug Pricing

Pharmacy Benefit Managers Affect Affordability of Prescription Drugs, Hurting Patients and Taxpayers For Immediate Release: April 16, 2026 Office of the Attorney General – Jennifer Davenport, Attorney General For Further Information: Media Inquiries- Allison Inserro OAGpress@njoag.gov View Comment Letter TRENTON — Attorney General Jennifer Davenport and a bipartisan coalition of 44 other attorneys general filed a comment letter in support of a proposed U.S. Department of Labor rule that would require transparency from pharmacy benefit managers (PBMs) that service employer-funded health plans. PBMs are third-party administrators of prescription drug programs for health insurers and health plans. Governor Mikie Sherrill called for more oversight into these middlemen in her budget address in March, noting that New Jersey’s Medicaid program would save $20 million annually if PBMs were not allowed to inflate prices. “We all feel the financial pain of rising drug prices, but it doesn’t have to be this way,” said Attorney General Davenport. “We’re standing together with a bipartisan coalition of attorneys general in urging the federal government to increase oversight over PBMs. Our office is committed to ensuring that PBMs are following the law—and to hold them accountable when they don’t.” Created in the late 1960s to process prescription drug claims, PBMs now play a far broader and more powerful role in the health care system by managing prescription drug benefits for health insurers. This includes, among other things, negotiating rebates and reimbursements with drug manufacturers and determining which drugs are covered and at what cost. Approximately 136 million Americans receive health coverage through an employer—either their own job or a family member’s—and the proposed rule responds to concerns that employers often lack visibility into how PBMs are making money or why drug costs change. It would require PBMs to disclose twice a year how they generate revenue and would give employers the right to audit them. PBMs have also long sought to avoid state regulation by claiming federal preemption under ERISA. The attorneys general urge the Department of Labor to clarify that the proposed rule does not preempt state PBM transparency laws. PBMs have long sought to avoid state regulation by claiming federal preemption under the Employee Retirement Income Security Act of 1974 (ERISA). Further, in the comment letter, the attorneys general ask the Department of Labor to commit to collaborating with state regulators to achieve transparency. According to the coalition, the final rule should mention that nothing in the rule is intended to prevent the Department of Labor from referring matters to state attorneys general, requesting their investigative or enforcement assistance, or coordinating with them when the department discovers violations of state law. Today, the top three PBMs manage approximately 80% of prescription drug claims. Due to the power imbalance held by PBMs and the negative effects of such power on drug pricing, all fifty states, the District of Columbia, and Puerto Rico have enacted laws to rein them in. In recent years, New Jersey has enacted several laws that apply to PBMs, including one that requires PBMs to report pricing information to the Division of Consumer Affairs and provides for civil penalties if they fail to report. In submitting today’s comment letter, Attorney General Davenport joins the attorneys general of Alaska, American Samoa, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, the District of Columbia, Georgia, Hawaii, Idaho, Illinois, Indiana, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Vermont, Virginia, Washington, West Virginia, and Wyoming. ### The post AG Davenport, Bipartisan Coalition Support Federal Rule to Increase PBM Transparency in Drug Pricing appeared first on New Jersey Office of Attorney General.

Apr 16, 202614 votes